Myelodysplastic syndrome · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Midostaurin monotherapy Variant #01 | — | R 76 418 | 28d | — | — | — | — | — |
Erlotinib monotherapy Variant #01 | — | R 13 907 | 28d | ~9.7 mo | ~8.8 mo | ~11 | ~R 152 976 PFS proxy · indirect | 30 |
Best supportive care Partial | — | — | — | — | ~8.5 mo | — | — | 3 |
3 of 3 regimens shown